347 Shares in DaVita Inc. (NYSE:DVA) Acquired by Friedenthal Financial

Friedenthal Financial acquired a new position in DaVita Inc. (NYSE:DVA) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 347 shares of the company’s stock, valued at approximately $48,000.

Other institutional investors also recently bought and sold shares of the company. Arizona State Retirement System boosted its stake in shares of DaVita by 1.4% during the 4th quarter. Arizona State Retirement System now owns 15,056 shares of the company’s stock worth $1,577,000 after acquiring an additional 210 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of DaVita during the 4th quarter valued at $1,097,000. DekaBank Deutsche Girozentrale boosted its holdings in DaVita by 25.2% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 11,428 shares of the company’s stock worth $1,186,000 after buying an additional 2,298 shares during the period. Allspring Global Investments Holdings LLC increased its stake in DaVita by 82.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 104,115 shares of the company’s stock worth $10,907,000 after buying an additional 47,166 shares in the last quarter. Finally, Sequoia Financial Advisors LLC purchased a new position in shares of DaVita in the fourth quarter valued at about $308,000. Institutional investors own 90.12% of the company’s stock.

DaVita Trading Down 0.4 %

DVA stock opened at $145.30 on Wednesday. The firm has a fifty day moving average price of $139.98 and a 200 day moving average price of $134.26. DaVita Inc. has a fifty-two week low of $71.51 and a fifty-two week high of $147.93. The firm has a market cap of $12.74 billion, a PE ratio of 16.57, a price-to-earnings-growth ratio of 0.81 and a beta of 0.87. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. The business had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The business’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the company posted $2.08 EPS. Sell-side analysts anticipate that DaVita Inc. will post 9.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Bank of America increased their target price on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. UBS Group increased their price objective on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Truist Financial upped their target price on shares of DaVita from $135.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, May 15th. StockNews.com downgraded shares of DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 8th. Finally, TD Cowen increased their price objective on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $154.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.